Advisors Capital Management LLC Acquires 5,034 Shares of Johnson & Johnson $JNJ

Key Points

• Advisors Capital Management increased its Johnson & Johnson stake by 1.0% in the second quarter, acquiring 5,034 shares and bringing its holdings to 526,560 shares valued at approximately $133.7 million. Institutional investors own 69.55% of J&J.
• Johnson & Johnson exceeded quarterly expectations, reporting $2.90 EPS and $25.31 billion in revenue, with revenue rising 6.6% year over year. The company reaffirmed 2026 EPS guidance of $11.60–$11.75.
• The company declared a quarterly dividend of $1.34 per share, equivalent to $5.36 annually and a 2.0% yield. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $268.22.

Advisors Capital Management LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1.0% in the second quarter, according to its most recent filing with the SEC. The fund owned 526,560 shares of the company's stock after acquiring an additional 5,034 shares during the period. Johnson & Johnson comprises 1.4% of Advisors Capital Management LLC's portfolio, making the stock its 12th biggest position. Advisors Capital Management LLC's holdings in Johnson & Johnson were worth $133,731,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the business. MJP Associates Inc. ADV increased its stake in Johnson & Johnson by 6.3% in the second quarter. MJP Associates Inc. ADV now owns 7,837 shares of the company's stock worth $1,990,000 after purchasing an additional 463 shares during the period. PCM Encore LLC boosted its stake in shares of Johnson & Johnson by 0.7% during the second quarter. PCM Encore LLC now owns 7,539 shares of the company's stock valued at $1,915,000 after purchasing an additional 53 shares during the period. Vise Technologies Inc. grew its holdings in shares of Johnson & Johnson by 109.5% in the second quarter. Vise Technologies Inc. now owns 211,863 shares of the company's stock worth $53,807,000 after purchasing an additional 110,745 shares during the last quarter. OVERSEA CHINESE BANKING Corp Ltd increased its stake in Johnson & Johnson by 59.9% in the 2nd quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 20,127 shares of the company's stock worth $5,112,000 after buying an additional 7,538 shares during the period. Finally, E Fund Management Co. Ltd. lifted its holdings in Johnson & Johnson by 9.6% during the 2nd quarter. E Fund Management Co. Ltd. now owns 28,709 shares of the company's stock valued at $7,291,000 after buying an additional 2,510 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $271.53 on Wednesday. The business has a 50-day simple moving average of $260.21 and a 200-day simple moving average of $244.39. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The stock has a market cap of $654.36 billion, a PE ratio of 31.46, a price-to-earnings-growth ratio of 2.54 and a beta of 0.24. Johnson & Johnson has a 52-week low of $173.33 and a 52-week high of $276.47.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm had revenue of $25.31 billion during the quarter, compared to analysts' expectations of $25.06 billion. During the same period in the previous year, the business posted $2.77 EPS. The business's revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities analysts expect that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be given a $1.34 dividend. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson's dividend payout ratio is 62.11%.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Defensive strength supported the stock. JNJ gained as the broader market weakened, suggesting investors favored its relatively stable healthcare business and dependable dividend. The company has maintained a decades-long dividend-growth streak, making it attractive to income-oriented investors. Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts
• Positive Sentiment: Upcoming results provide a potential catalyst. Johnson & Johnson will host its third-quarter earnings conference call on October 13. Investors will focus on operating trends, guidance and updates on key risks. Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
• Neutral Sentiment: J&J’s investment portfolio received favorable attention. The company owns stakes in approximately 15 biotechnology and medical-technology companies, with one larger holding standing out because of its market capitalization. The portfolio may offer strategic or financial upside, but it is not currently a major earnings catalyst. Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.
• Negative Sentiment: One analyst modestly reduced its earnings forecast. Erste Group Bank lowered its 2026 EPS estimate to $11.65 from $11.68, although the revised forecast remains above the broader consensus estimate of $11.61. The small cut is a mild negative signal rather than a material change to the outlook.
• Negative Sentiment: Dividend investors face a longer-term uncertainty. Commentary comparing JNJ with Procter & Gamble highlights a forthcoming corporate event that could threaten the uninterrupted payout record investors associate with J&J. The article does not indicate an immediate dividend reduction, but the issue may temper enthusiasm among income-focused shareholders. Why Procter & Gamble’s Quieter Dividend Outpaces Johnson & Johnson’s Growth Story

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Raymond James Financial set a $280.00 target price on Johnson & Johnson in a report on Monday, August 3rd. Bank of America increased their price target on shares of Johnson & Johnson from $254.00 to $263.00 and gave the company a "neutral" rating in a research report on Friday, July 10th. Royal Bank Of Canada increased their price objective on Johnson & Johnson from $265.00 to $287.00 and gave the company an "outperform" rating in a report on Monday, July 13th. Stifel Nicolaus set a $260.00 target price on Johnson & Johnson in a research report on Wednesday, July 15th. Finally, The Goldman Sachs Group reissued a "buy" rating and issued a $282.00 price target on shares of Johnson & Johnson in a report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus price target of $268.22.

Insider Activity

In other news, EVP Vanessa Broadhurst sold 23,054 shares of the company's stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the transaction, the executive vice president directly owned 23,003 shares of the company's stock, valued at $5,779,963.81. This represents a 50.06% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Kathryn E. Wengel sold 10,000 shares of the company's stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president owned 114,288 shares of the company's stock, valued at $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 63,972 shares of company stock valued at $16,245,605. Insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source